AAPG News & Events

Ascentage Pharma "announced that its novel next-generation Bruton's tyrosine kinase-targeted protein degrader, APG-3288, has received investigational new drug application clearance from the China Center for Drug Evaluation and is poised to enter a clinical study in patients with relapsed/refractory hematologic malignancies. This IND clearance from the China CDE, which came shortly after the IND was cleared by the U.S. Food and Drug Administration, ushers in a new phase in the multicenter clinical development of APG-3288 and highlights Ascentage Pharma's robust global development capabilities in the field of targeted protein degradation. Ascentage Pharma will be conducting a multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies."

Ascentage Pharma announced that its novel next-generation BTK-targeted protein degrader, APG-3288, has received the IND clearance from the U.S. Food and Drug Administration and is poised to enter a clinical study in patients with relapsed/refractory B-cell malignancies. This clearance officially opens the chapter on Ascentage Pharma's clinical development in the field of targeted degradation and marks another major expansion to the company's global innovative pipeline, the company said. This is a global, multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies.